1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL
Cells · 12.08.2026 · 15 (16) · 1450
DOI: 10.3390/cells15161450 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 12.08.2026. Verfasst von Hanxu Qian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Center of Technology Innovation for Molecular Targeting and Intelligent Diagnosis and Treatment, Shandong Key Lab of Complex Medical Intelli…. Hauptthemen laut MEDLINE: Sorafenib, Proto-Oncogene Proteins c-met, Carcinoma, Renal Cell, Drug Resistance, Neoplasm. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Taishan Scholar Program, the Key R&D Program of Shandong Province, China, the Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Sorafenib is widely used to treat metastatic renal cell carcinoma (RCC); however, the acquired drug resistance limits its efficacy and application in clinical practice. The receptor tyrosine kinases c-Met and AXL play important roles in cancer progression and are involved in tyrosine kinase inhibitor-induced drug resistance in cancers, but whether these two receptors also contribute to sorafenib-induced drug resistance in RCC is unclear. In this study, we evaluated our synthesized compound 1D228, a TKI derived from Tepotinib, in sorafenib-resistant RCC models, which demonstrated further inhibition in sorafenib-resistant RCC cells, and induced 25% more reduction in resistant RCC tumor size by 1D228 combined with sorafenib compared with sorafenib monotherapy in animal models. Mechanistically, resistant RCC exhibited elevated phosphorylation of c-Met and AXL, which was effectively suppressed by 1D228. These findings indicated that compound 1D228 sensitized the sorafenib resistance of RCC by dual targeting the c-Met and AXL signaling pathways. This study suggests that 1D228 may represent a promising preclinical therapeutic strategy for RCC patients with sorafenib resistance mediated by c-Met and AXL activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Center of Technology Innovation for Molecular Targeting and Intelligent Diagnosis and Treatment, Shandong Key Lab of Complex Medical Intelligence and Aging, Shandong Medical and Pharmaceutical University, Yanta…
- Medicine and Pharmacy Research Center, Shandong Medical and Pharmaceutical University, Yantai 264003, China.
- Department of Oncology, Shandong Medical and Pharmaceutical University Hospital, 522 Huanghe 3rd Road, Binzhou 256603, China.
ORCID-Profile: Baijiao An, Yin Zhang
Förderung
- the Taishan Scholar Program
- the Key R&D Program of Shandong Province, China
- the Natural Science Foundation of Shandong Province
- Binzhou Medical University Starting Funding
- The Youth Science Foundation project of Shandong Province Natural Science Foundation
- Binzhou Medical University
- National Natural Science Foundation of China
- the “Case-by-Case Introduction of Top Talent (Teams)” Program in Yantai
Zitieren
APA
Qian, H., Ren, H., Xu, L., Hu, X., Sun, Y., Ju, Q., Zhang, C., Liu, S., An, B., Yang, C., Liu, X., & Zhang, Y. (2026). 1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL. Cells, 15(16), 1450. https://doi.org/10.3390/cells15161450
Vancouver
Qian H, Ren H, Xu L, Hu X, Sun Y, Ju Q, et al. 1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL. Cells. 2026;15(16):1450. doi:10.3390/cells15161450
BibTeX
@article{Qian2026,
author = {Qian, Hanxu and Ren, Huimin and Xu, Lei and Hu, Xingge and Sun, Yihong and Ju, Qing and Zhang, Chenguo and Liu, Shuo and An, Baijiao and Yang, Chunhua and Liu, Xingjie and Zhang, Yin},
title = {1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL},
journal = {Cells},
year = {2026},
volume = {15},
number = {16},
pages = {1450},
doi = {10.3390/cells15161450}
}
EUVIMED